Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. [electronic resource]
Producer: 20100308Description: 57-65 p. digitalISSN:- 0008-543X
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Benzenesulfonates -- administration & dosage
- Biomarkers, Tumor -- analysis
- Carcinoma, Renal Cell -- drug therapy
- Disease-Free Survival
- Female
- Humans
- Interferon-alpha -- administration & dosage
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Pyridines -- administration & dosage
- Sorafenib
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.